Racemic

The racemic p53 and MDM2 proteins-interaction-inhibitor is an inhibitor of the interaction between p53 and MDM2 proteins.

AG-120 (racemic), the racemic mixture of AG-120, is an orally available isocitrate dehydrogenase type 1 (IDH1) inhibitor, and shows potential antineoplastic activity.

Rasagiline 13C3 mesylate racemic is the deuterium labeled Rasagiline, which is an irreversible monoamine oxidase inhibitor.

Racemic Naproxen is a biochemical substance.

GNE-140 racemic is a potent lactate dehydrogenase (LDHA) inhibitor.

Racemic Tamsulosin is a biochemical.

Racemic rasagiline, also known as AGN-1135, is a Monoamine Oxidase type-B inhibitor (MAOI). However, application of this drug can lead to fatal hypertensive crisis in patients who consume tyramine-rich foods. TVP-1022 is the (S)-isomer os Rasagiline and acts as a cardioprotective agent.

K858 Racemic (K858) is a selective mitotic kinesin Eg5 inhibitor which acts in an ATP-noncompetitive manner.

Tertatolol is an effective antagonist of beta-adrenoceptor and 5-HT receptors.

Saphenamycin is an antibiotic from a strain of Streptomyces.

EF1502 is a potent and selective GABA transporter inhibitor.

(±)-Dihydrozeatin is a zeatin derivative, suitable for biochemical experiments and drug synthesis research.

Rac-Efavirenz is a non stereospecific structure of Efavirenz.

S07-2005 racemic is a chemically potent and selective inhibitor of aldo-keto reductase 1C3 (AKR1C3), with an IC50 value of 0.13 μM and 0.75 μM for AKR1C3 and AKR1C4, respectively. Due to its inhibitory properties, it exhibits potential as a chemotherapeutic potentiator, specifically in the context of overcoming drug resistance in cancer [1].

Idazoxan is an alpha2 receptor antagonist that also exhibits activity at imidazoline [I1] and [I2] receptors, playing a role in modulating dopamine release.

Amlodipine-d4 Maleate (Racemic) is a deuterated compound of Amlodipine Maleate (Racemic). Amlodipine Maleate (Racemic) has a CAS number of 88150-47-4. Amlodipine maleate is an orally active dihydropyridine calcium channel blocker that inhibits calcium inward flow by blocking voltage-dependent L-type calcium channels.Amlodipine maleate is used in the study of hypertension and cancer.

Pyruvic acid (Acetylformic acid) is an intermediate compound in the metabolism of carbohydrates, proteins, and fats. In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures.

N-0861 racemate is the racemic mixture of N-0861.

(Rac)-Acolbifene (EM-343) is the racemic form of Acolbifene. Acolbifene is a estrogen receptor antagonist. (Rac)-Acolbifene exhibits anti-estrogenic and estrogenic activities. (Rac)-Acolbifene contains a piperidine ring and exhibits good pharmacological profile,relative binding affinity (RBA)=380.

WAY127093B racemate is the racemic mixture of WAY127093B, a phosphodiesterase IV inhibitor with demonstrated oral activity in rats and guinea pigs.

Rentiapril racemate (SA-446 racemate) is the racemic form of Rentiapril, exhibiting anti-inflammatory properties and potential applications in glaucoma research.

(RS)-4-Carboxyphenylglycine is a racemic mixture. (S)-4-Carboxyphenylglycine is a selective mGlu1α receptor antagonist.

(Rac)-RK-682 is a racemic mixture that functions as a protein tyrosine phosphatases (PTPases) inhibitor, specifically targeting protein tyrosine phosphatase 1B (PTP-1B), low molecular weight protein tyrosine phosphatases (LMW-PTP), and cell division cycle 25B (CDC-25B), with inhibitory concentrations (IC50s) of 8.6 μM, 12.4 μM, and 0.7 μM, respectively [1].

Vutiglabridin (HSG4112) is a novel and safe modulator of PON2, a racemic compound. vutiglabridin is an optimized structural analogue of Glabridin and is superior to Glabridin in terms of weight loss and chemical stability. vutiglabridin ameliorates mptp-induced neurodegeneration in Parkinson's disease mice by targeting mitochondrial paraoxonase-2. Vutiglabridin is a clinical phase 2 drug for the treatment of obesity and has therapeutic effects on p-mitochondrial PON2 in a PD model. vutiglabridin penetrates the brain, binds PON2, and restores 1-methyl-4-phenylpyridine (MPP*)-induced neuroblastoma in SH-SY5Y Vutiglabridin significantly attenuated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dyskinesia and dopaminergic neuronal damage in mice modeled with PD in mouse experiments.